

Company Overview



About Us

- Belgian biotechnology company.
- Advanced therapies for **Liver repair and organ regeneration.**
- In **Phase IIb** for an **alternative to liver transplantation, life saving indication**


Mission

Clinical development to market approval of signaling cell technologies in life saving indications

Vision

Cell Signaling Technology for Liver Repair & Organ Regeneration
Repair the native liver

Technology: Signaling Cell Platform - HepaStem®




Current Positioning

<p style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; color: #e91e63;">Organ</p> <p style="text-align: center; font-weight: bold; color: white;">LIVER</p> <p>The liver is the master organ of the body Failure of the liver causes failure of all vital organs</p>	<p style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; color: #e91e63;">Diseases area</p> <p>Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis, Acute Decompensation of Cirrhosis, NASH</p>	<p style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; color: #e91e63;">First target</p> <p>Acute on Chronic Liver Failure (ACLF)</p> <p>Multiorgan failure complicating underlying chronic Liver disease</p>	<p style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; color: #e91e63;">Therapeutic Solution</p> <p>HepaStem® is an allogeneic Advanced Therapy derived from the liver</p> <p>Simple intravenous infusion, homing to the liver, in situ immunomodulatory and antifibrotic properties.</p>	<p style="writing-mode: vertical-rl; transform: rotate(180deg); font-weight: bold; color: #e91e63;">ACLF market</p> <p>Life saving indication</p> <p>Highly unmet need</p> <p>Alternative to liver transplantation 96,000 patients affected/year (EU ,US, Cn, Jpn)</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Production

Fully-Formed Supply Chain, Production & Platform




Product Pipeline

Potential breakthrough for Life Threatening diseases as alternative to Liver Transplantation

Technologies	Indications	R&D	Preclinical	Phase I	Phase IIa / IIb
HEPASTEM®	ACLF	[Progress bar]			
HEPASTEM	(N)ASH	[Progress bar]			
HEPASTEM	AD	[Progress bar]			
HEPASTEM®	UCD	[Progress bar]			
HEPASTEM 2 ND	Liver Cancer	[Progress bar]			

Regulatory & Market Access



Unique Opportunity

Team & Track record

Etienne Sokal, M.D., Ph.D.
CEO/CMO Cellaion Founder

Mustapha Najimi, Ph.D.
CSO

Eric Pauly
Head of Operations & CMC

Virginie Barthel
Head of Clinical Operations

Noelia Gordillo, M.D
Head of Medical Affairs

Bruno De Keersmaecker
Head of Finance

- Team with long standing biotech experience
- Large network of Key opinion Leaders and hepatologists
- Focus on market authorization, accelerated approval


Clinical

- Phase IIB ongoing
- >100 patients treated in previous and current trial
- Encouraging preliminary efficacy results in phase IIA
- Recruiting phase IIB study
- Conditional approval sought for 2025

IP

- 14 different patent families
- Protected till >2040
- More than 150 patents & patents applications on a global basis

Potential Market



Investment opportunity

- Acquisition of full IP & assets of an advanced therapy platform targeting inflammation
- Very **attractive pre money value**
- Ongoing Serie A aiming to reach CSR of phase IIB.
- Financing round still open.
- Open to Partnership to develop new indications/licensing deal.

Get In Touch: ir@cellaion.com